全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Atypical Central Neurocytoma with Recurrent Spinal Dissemination over a Period of 20 Years: A Case Report and Review of the Literature

DOI: 10.1155/2013/925647

Full-Text   Cite this paper   Add to My Lib

Abstract:

We present an unusual case of a late recurrent central neurocytoma that was rediagnosed as an ependymoma and neurocytoma in accordance with changes in histological classifications. Case Description. A 56-year-old male teacher presented with incomplete transverse syndrome due to several intradural extramedullary tumors at the level of lumbar vertebrae 1–3. The histological diagnosis at the time was atypical ependymoma. One year later, two additional tumors were removed at the L5-S1 vertebral level. For 12 years, the patient remained tumor free on followup. Fourteen years after the initial diagnosis, the patient presented with thoracic paresthesias due to two new extramedullary tumors in the C7-T1 and the T8-T9 vertebral levels. After complete removal of the tumors, a radiological survey revealed an intracranial lesion in the third ventricle. Five months later, an additional lesion recurrence was removed surgically. The most recent histological diagnosis revealed an atypical central neurocytoma. In retrospect, the previous tumors were reclassified as neurocytoma according to the additional immunohistochemistry evidence. Discussion. There is no standard adjuvant treatment regimen for atypical neurocytoma; therefore, the patient is currently under close followup. Modern histopathological diagnosis is essential in these cases. Potential routes for dissemination of the tumor should be considered upon first recurrence. 1. Introduction Central neurocytomas are rare benign tumors of the central nervous system, characterized by their intraventricular localization. They are considered to arise from precursor cells of the septum pellucidum. They predominantly occur in young adults and generally have a favorable outcome, although cases with an aggressive clinical course and recurrences have been described. Historically, many of these lesions were regarded as either intraventricular oligodendroglioma or as ependymoma until detailed immunohistological clarification of their neuronal phenotypes was established. Neurocytoma was first described by Hassoun et al. [1] and is now a well-established diagnosis included in the latest WHO Classification [2]. In the literature, only a few neurocytomas were reported with an extraventricular location, including cerebral hemispheres [3], thalamus [4], cerebellum [5], pons [6], amygdala [7], retina [8], and in some rare cases the spinal cord [9]. Herein, we report a case of an atypical central neurocytoma with recurrent spinal dissemination over a period of 20 years. 2. Case Report A 56-year-old Caucasian male teacher was first seen

References

[1]  J. Hassoun, D. Gambarelli, F. Grisoli, et al., “Central neurocytoma. An electron-microscopic study of two cases,” Acta Neuropathologica, vol. 56, no. 2, pp. 151–156, 1982.
[2]  D. N. Louis, H. Ohgaki, O. Wiestler, et al., The 2007 WHO Classification of Tumors of the Central Nervous System, IARC Press, Lyon, France, 2007.
[3]  D. J. Brat, B. W. Scheithauer, C. G. Eberhart, and P. C. Burger, “Extraventricular neurocytomas: pathologic features and clinical outcome,” American Journal of Surgical Pathology, vol. 25, no. 10, pp. 1252–1260, 2001.
[4]  S. Sgouros, A. R. Walsh, and P. Barber, “Central neurocytoma of thalamic origin,” British Journal of Neurosurgery, vol. 8, no. 3, pp. 373–376, 1994.
[5]  L. Pal, V. Santosh, N. Gayathri et al., “Neurocytoma/rhabdomyoma (myoneurocytoma) of the cerebellum,” Acta Neuropathologica, vol. 95, no. 3, pp. 318–323, 1998.
[6]  V. Soontornniyomkij and R. L. Schelper, “Pontine neurocytoma,” Journal of Clinical Pathology, vol. 49, no. 9, pp. 764–765, 1996.
[7]  A. L. Rabinowicz, L. E. Abrey, D. R. Hinton, and W. T. Couldwell, “Cerebral neurocytoma: an unusual cause of refractory epilepsy. Case report and review of the literature,” Epilepsia, vol. 36, no. 12, pp. 1237–1240, 1995.
[8]  C. Metcalf, E. M. Mele, and I. McAllister, “Neurocytoma of the retina,” British Journal of Ophthalmology, vol. 77, no. 6, pp. 382–384, 1993.
[9]  S. Sharma, C. Sarkar, S. Gaikwad, A. Suri, and M. C. Sharma, “Primary neurocytoma of the spinal cord: a case report and review of literature,” Journal of Neuro-Oncology, vol. 74, no. 1, pp. 47–52, 2005.
[10]  H. Takao, K. Nakagawa, and K. Ohtomo, “Central neurocytoma with craniospinal dissemination,” Journal of Neuro-Oncology, vol. 61, no. 3, pp. 255–259, 2003.
[11]  A. A. Brandes, P. Amistà, M. Gardiman, L. Volpin, D. Danieli, and B. Guglielmi, “Chemotherapy in patients with recurrent and progressive central neurocytoma,” Cancer, vol. 88, pp. 169–174, 2000.
[12]  G. Elek, F. Slowik, L. Eross, S. Tóth, Z. Szabó, and K. Bálint, “Central neurocytoma with malignant course: neuronal and glial differentiation and craniospinal dissemination,” Pathology and Oncology Research, vol. 5, no. 2, pp. 155–159, 1999.
[13]  D. Y. Eng, F. DeMonte, L. Ginsberg, G. N. Fuller, and K. Jaeckle, “Craniospinal dissemination of central neurocytoma. Report of two cases,” Journal of Neurosurgery, vol. 86, no. 3, pp. 547–552, 1997.
[14]  N. Tomura, H. Hirano, O. Watanabe et al., “Central neurocytoma with clinically malignant behavior,” American Journal of Neuroradiology, vol. 18, no. 6, pp. 1175–1178, 1997.
[15]  T. Fujimaki, A. Matsuno, T. Sasaki et al., “Proliferative activity of central neurocytoma: measurement of tumor volume doubling time, MIB-1 staining index and bromodeoxyuridine labeling index,” Journal of Neuro-Oncology, vol. 32, no. 2, pp. 103–109, 1997.
[16]  F. S?ylemezoglu, B. W. Scheithauer, J. Esteve, and P. Kleihues, “Atypical central neurocytoma,” Journal of Neuropathology & Experimental Neurology, vol. 56, pp. 551–556, 1997.
[17]  M. C. Sharma, A. Rathore, A. K. Karak, and C. Sarkar, “A study of proliferative markers in central neurocytoma,” Pathology, vol. 30, no. 4, pp. 355–359, 1998.
[18]  D. Rades, S. E. Schild, and F. Fehlauer, “Prognostic value of the MIB-1 labeling index for central neurocytomas,” Neurology, vol. 62, no. 6, pp. 987–989, 2004.
[19]  E. Achilles, B.-C. Padberg, K. Holl, G. Kloppel, and S. Schroder, “Immunocytochemistry of paragangliomas—value of staining for S-100 protein and glial fibrillary acid protein in diagnosis and prognosis,” Histopathology, vol. 18, no. 5, pp. 453–458, 1991.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413